Analytical Data
-
Gene name
KLK2
- Application
-
Alternative Names
KLK2;Kallikrein-2
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P20151
-
Expression Region
25-261aa
-
AA Sequence
MGSSHHHHHHSSGLVPRGSHMGSIVGGWECEKHSQPWQVAVYSHGWAHCG GVLVHPQWVLTAAHCLKKNSQVWLGRHNLFEPEDTGQRVPVSHSFPHPLY NMSLLKHQSLRPDEDSSHDLMLLRLSEPAKITDVVKVLGLPTQEPALGTT CYASGWGSIEPEEFLRPRSLQCVSLHLLSNDMCARAYSEKVTEFMLCAGL WTGGKDTCGGDSGGPLVCNGVLQGITSWGPEPCALPEKPAVYTKVVHYRK WIKDTIAANP
-
Molecular Weight
29 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
KLK2 (Kallikrein-related peptidase 2) is a serine protease that belongs to the kallikrein family and is primarily expressed in the prostate, making it a crucial biomarker for prostate cancer diagnostics. Its elevation in serum levels is associated with the presence of prostate cancer, distinguishing it from other conditions and aiding in the assessment of disease progression. Research into KLK2 recombinant proteins aims to better understand its structure, function, and interactions within the context of cancer biology. Additionally, KLK2 serves as a potential target for therapeutic interventions and vaccine development, paving the way for innovative treatments in prostate cancer management. The use of recombinant technology allows for the production of large quantities of KLK2 for further study, including experimental assays that elucidate its enzymatic properties and role in tumorigenesis. By studying KLK2 in detail, researchers hope to uncover insights that could lead to improved diagnostic tools and novel therapeutic strategies, ultimately enhancing patient care in prostate cancer treatment.











